Solstein Capital’s AstraZeneca AZN Stock Holding History

Solstein Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.71K	Buy	+9	New	+$1.69K	﹤0.01%	398
2026 Q1	–	Sell	-10	Closed	-$1.75K	–	452
2025 Q4	$1.75K	Hold	10	–	–	﹤0.01%	421
2025 Q3	$1.46K	Hold	10	–	–	﹤0.01%	419
2025 Q2	$1.33K	Hold	10	–	–	﹤0.01%	460
2025 Q1	$1.4K	Hold	10	–	–	﹤0.01%	307
2024 Q4	$1.25K	Hold	10	–	–	﹤0.01%	305
2024 Q3	$1.48K	Hold	10	–	–	﹤0.01%	303
2024 Q2	$1.48K	Hold	10	–	–	﹤0.01%	304
2024 Q1	$1.29K	Hold	10	–	–	﹤0.01%	301
2023 Q4	$1.28K	Hold	10	–	–	﹤0.01%	300
2023 Q3	$1.29K	Hold	10	–	–	﹤0.01%	301
2023 Q2	$1.36K	Hold	10	–	–	﹤0.01%	299
2023 Q1	$1.32K	Hold	10	–	–	﹤0.01%	266
2022 Q4	$1.29K	Hold	10	–	–	﹤0.01%	281
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	295
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	337
2022 Q1	$1K	Hold	10	–	–	﹤0.01%	369
2021 Q4	$1K	Hold	10	–	–	﹤0.01%	406
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	445
2021 Q2	$1K	Buy	+10	New	+$1.1K	﹤0.01%	427

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Solstein Capital's AZN Position: Q2 2026 in Review

Solstein Capital opened a new position in AstraZeneca (AZN) in Q2 2026: 9 shares worth $1.71K. The stake represents ﹤0.01% of the portfolio and ranks #398 among its holdings. This is a return to the name: Solstein Capital previously reported a position in AZN as recently as Q4 2025.

Solstein Capital first reported a position in AZN in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.75K in Q4 2025. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Solstein Capital held 9 shares of AstraZeneca worth $1.71K as of Q2 2026.
AstraZeneca was a new Solstein Capital position in Q2 2026.
AstraZeneca made up ﹤0.01% of Solstein Capital's portfolio in Q2 2026, its #398 holding.
Solstein Capital first reported a position in AstraZeneca in Q2 2021 and has held it in 20 quarters since.
Solstein Capital's AstraZeneca position peaked at $1.75K in Q4 2025.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Solstein Capital's 13F filing for Q2 2026, filed 13 Aug 2026.